News | November 10, 2023
SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Subscribe To Our Newsletter & Stay Updated
